Abstract: Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is a rare autosomal recessive inborn error of mitochondrial fatty acid oxidation. It is caused by rare mutations as well as polymorphic susceptibility variants. We describe here the case of a 1-year-old male patient who had growth and mental retardation, seizures, and recurring fever since infancy. Urinary gas chromatography/mass spectrometry (GC/MS) showed elevated levels of ethylmalonic acid. Plasma acylcarnitines on tandem mass spectrometry (MS/MS) and elevations of C4-cartinitine are consistently present. The two polymorphic susceptibility variants of the short-chain acyl-CoA dehydrogenase (SCAD) gene, c.625G > A and c.322G > A, were detected. Because of its highly variable clinical characteristics, there are no related reports in China. This report broadens the phenotype and genotype of SCADD in China and underlines the difficulty of diagnosis.
Introduction
Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is a disorder of the mitochondrial fatty acid oxidation with a heterogeneous clinical and biochemical pattern (1) . A severe phenotype was originally described, but currently, most patients are diagnosed through newborn screening using tandem mass spectrometry and remain asymptomatic (2) . Neuromuscular signs are the main clinical characteristics of SCADD. Elevated urinary ethylmalonic acid (EMA) and plasma butyrylcarnitine are the markers of functional deficiency of short-chain acyl-CoA dehydrogenase (SCAD) (3) . Here we present a child with growth retardation, hypotonia, seizures, and a SCAD gene variation.
Case report
The patient, a 1-year-old boy, is the second child of healthy non-consanguineous parents. His birth weight was 3800 g, and he did not require resuscitation. His older sister is healthy. When he was born, he experienced fever, seizures, hyponatremia, and hypocalcemia. After a week of hospitalization, he recovered, but he showed growth development delay, such as being unable to hold his head up until 5 months or to sit without support. At 10 months, he can speak one to two words. Three months earlier, he experience diarrhea with fever, seizures, hypotonia, growth retardation, and poor feeding. Hence, he was admitted to our hospital.
On physical examination, the patient ' s weight was 8.7 kg. He showed no dysmorphic feature. The cardiovascular examination was normal, with regular rate and rhythm, and there were no rubs or murmurs. The lungs were clear, and the abdomen was soft. He was found to have axial hypotonia. A weakness on all limbs was evident, and it was particularly prominent in the arms. Deep tendon reflexes were normal. Electroencephalography showed normal brain rhythms, but brain magnetic resonance imaging and computed tomography showed leukodystrophy.
The creatine kinase level was 130 (45 -390) U/L. The level of blood ammonia was 67 (10 -47) μ mol/L. Through tandem mass spectrometry, the plasma butyrylcarnitine level was found to be increased on two occasions (2.94 and 2.03 μ mol/L; normal range, 0.00 -0.83 μ mol/L). Urinary organic acids showed a moderately increased EMA, with accompanying methylsuccinic acid in two successive samples. The SCAD encoding gene, ACADS, was fully sequenced, revealing the two polymorphic susceptibility variants c625G > A and c322G > A.
To minimize the episodes of metabolic imbalance, the patient was treated with nasal feeding and carnitine supplementation. At half-year follow-up, no new episodes of seizures or growth retardation had occurred.
Discussion and conclusions
There have been no reports of Chinese patients with SCADD; hence, this is the first case report in China of SCADD, which was diagnosed through biochemical and genetic analyses (4) . The SCAD is a mitochondrial enzyme that catalyzes the dehydrogenation of short-chain fatty acids (C4 -C6), which initiate the cycle of β -oxidation. Without the SCAD ' s enzyme activity, toxic intermediates accumulate, including butyrylcarnitine, butyrylglycine, and EMA, which lead to a toxic effect on neuronal and muscular tissue (5) . Neuromuscular symptoms are most frequently reported, for example, growth developmental delay, epilepsy, behavioral disorders (6) . In this patient, his clinical picture was characterized by neurological symptoms, such as developmental delay and hypotonia. After experiencing infection and/or fever, his condition became much more severe, with poor feeding, growth retardation, and seizure. Biochemical (elevated urinary EMA and plasm butyrylcarnitine) and molecular genetic results (compound heterozygous polymorphism c625G > A and c322G > A) allowed us to make a reliable diagnosis of SCADD. To avoid the metabolic crisis, the patient was successfully treated with nasal feeding and carnitine supplementation.
An early diagnosis might be critical in reducing the risk for metabolic decompensation, and genetic analysis is essential in confirming SCADD. As far as we know, there are about 60 mutations in the SCADD gene (ACADS) (7) . Based on SCADD gene mutations, this disease can be classified into two forms (8) . In the classic form, the defect is caused by two inactivating mutations that result in very low undetectable residual enzyme activity. In the other form, the two polymorphic variations (c.511C > T and c.625G > A) are present in a homozygous or compound heterozygous form alone or together with heterozygosity (7, 9) . It has been demonstrated that the c.625G > A polymorphism is associated with an increased incidence of elevated EMA aciduria (10) . In our patient, EMA is elevated in two successive samples; thus, an assay for the common polymorphisms is warranted. After the DNA sequencing, the c.625G > A and c.322G > A heterozygous forms have been detected. Earlier studies showed that a common variant protein (c.625G > A) caused severe misfolding, and this may lead to the degradation and accumulation of the abnormal protein. The abnormal protein affects the stability of the SCAD enzyme, which decreases enzyme activity (11) . To elucidate the pathogenesis of SCADD, the molecular properties of some novel mutations have been investigated, such as G108D (c.323G > A) (12) . The studies reported that the expression of ACADS-encoded mutation proteins would give rise to mitochondrial fragmentation and autophagy, which also lead to the destruction of the SCAD enzyme function (13) . Although the enzymatic activities were not determined in this patient, we assumed that the c.625G > A and c.322G > A compound heterozygosity influenced the SCAD protein ' s stability and function.
In conclusion, we have described the case of a Chinese pediatric patient with SCADD who was diagnosed through biochemical analysis and molecular study, and it is hoped that this will contribute to a better understanding of the clinical and genetic background of Chinese SCADD patients. However, further study is needed to investigate the functional and structural changes of the proteins involved in this disorder and their association with clinical findings.
